Omitting donepezil is hardly a hardship

BMJ

Volumn 335, Issue 7627, 2007, Pages 954-

  Finucane, Thomas E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; PLACEBO;

CLINICAL RESEARCH; CLINICAL TRIAL; DEMENTIA; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HUMAN; LETTER; PRIORITY JOURNAL;

EID: 36348995350     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.39388.433137.1F     Document Type: Letter

References (3)

1. Gulland A. NICE guidelines create ethical dilemmas in care of elderly people, says report. BMJ 2007; 335: 791. (20 October.) doi:10.1136/bmj.39371.570509.DB
2. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al, AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-15.
3. Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, et al; CALM-AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357: 1382-92.